About Us

Our Mission Statement

Saringer Life Science Technologies is a North American company dedicated to the design, manufacture, and distribution of innovative drug-free solutions to common medical problems including pain, chronic pain, vascular conditions, prevention of Deep Vein Thrombosis (DVT), and wound healing.  Our products are designed to help people suffering from debilitating medical conditions lead active healthy lifestyles, without the use of common pharmaceutical drugs.

About Us

For more than 35 years, John Saringer, the founder and CEO of Saringer Life Sciences, has been developing advanced technologies for mobilizing the human body. Since graduating from the University of Toronto as a Professional Engineer (1977), he has been specializing in biomechanics and the development of products to accelerate healing and mitigate the effects of immobility. In the early 1980s, he was a Research Associate at the University of Toronto and a Ph.D. Candidate at McMaster University but left academia in 1982 to build Toronto Medical Corp, where he was the CEO and director of R&D until the company was sold in 1997.

In 1978, Saringer and Dr. R.B. Salter began their 20-year collaboration designing and building passive movement devices. Together they promoted the worldwide acceptance and commercialization of Continuous Passive Motion (CPM) technology.

Since then, Saringer has developed other products such as the ICEOtherm, a device for treating chronic pain, and the Venowave, a portable compression pump which increases blood circulation and helps to mitigate the harmful effects of immobility.

About Our Team

John Saringer

President and CEO

John Saringer is a successful engineer, inventor and entrepreneur. He began his career as an academic, doing biomedical research and teaching statistics to engineering students at the University of Toronto. John has eighteen U.S. and Canadian patents to his credit, and more pending, and over 30 patents from other jurisdictions. Having worked with various medical device technologies over the past thirty years, John brings technical and design leadership to Saringer Life Science Technologies.

Dr. Jack Hirsh

Chief Scientific Officer and Professor Emeritus, McMaster University

Dr. Jack Hirsh, professor emeritus in medicine and director of the Henderson Research Centre, is an internationally recognized clinician and scientist in anticoagulant therapy and thrombosis. Dr. Hirsh is a member of the Order of Canada, a recipient of the International Gairdner Research Award, and a Fellow of the Royal Society of Canada, Dr. Hirsh has developed a world-renowned program for the diagnosis, prevention, and treatment of thrombosis (abnormal blood clots) and atherosclerosis. Dr. Hirsh has been instrumental in the planning and execution of the clinical trials for both the Venowave and the ICE-O-therm.

Dr. Robert Kaplan

Associate Professor in the Division of Cardiology, and Director of the Vascular Medicine Clinic, Hamilton Health Sciences

Dr. Anand is a Professor of Medicine and Epidemiology at McMaster University, the Director of McMaster Population Genomics Program and a vascular medicine specialist. She recently received the Canada Research Chair in Ethnic Diversity and Cardiovascular Disease. She also holds both the new Heart and Stroke Foundation of Ontario/Michael G. DeGroote Chair in Population Health Research, as well as the Eli Lily/May Cohen Chair in Women’s Health Research at McMaster. Her present research focuses upon the environmental and genetic determinants of vascular disease in populations of varying ancestral origin, women and cardiovascular disease, and peripheral vascular disease.

Dr. John Eikelboom

Associate Professor in the Department of Medicine at McMaster University in Hamilton, Ontario

After earning his MBBS degree at the University of Western Australia Medical School, Australia, he completed training in Internal Medicine and Haematology at Royal Perth Hospital, Australia, and trained in Epidemiology and Thrombosis Medicine at McMaster University. He holds a Canada Research Chair in Cardiovascular Medicine from the Canadian Institutes for Health Research. Dr. Eikelboom’s current research focuses on variable response to antiplatelet therapy, antithrombotic therapy in atrial fibrillation, and mechanisms and prognosis of bleeding. He has published more than 150 peer-reviewed papers. He is a member of the Editorial Board for Stroke and on the Advisory Board for the Journal of Thrombosis and Haemostasis.

Dr. Jeff Ginsberg

Professor, Division of Hematology and Thromboembolism, Department of Medicine at McMaster University in Hamilton, Ontario

Dr. Ginsberg was the Director of the Clinical Thromboembolism Group (CTG) at the Henderson Research Centre from 1999 to 2005. He graduated from medical school at the University of Ottawa in 1978 and was elected into the Alpha Omega Alpha Medical Society. After a brief stint as a military physician, he completed Internal Medicine and Hematology training at the University of Toronto. He came to Hamilton in 1986 as a Research Fellow of the Heart & Stroke Foundation of Canada under the supervision of Dr. Hirsh and became the Chief of the Thromboembolism Service at Chedoke-McMaster Hospitals in 1988. Since then, he has had continuous personal support, first as a Research Scholar of the Heart and Stroke Foundation of Canada and then, for the last 7 years as a Career Investigator of the Heart and Stroke Foundation of Ontario. He also holds a Research Chair from CIHR/UI and has been awarded the Fortino’s Distinguished Scientist Award, a five-year award for outstanding research of the Heart and Stroke Foundation of Ontario.

In September 2005 he received the inaugural award of the David Braley and Nancy Gordon Chair in Thromboembolic Disease. He has been successful in obtaining many peer-reviewed grants from H&SFO, CIHR/MRC, NHRDP, and PSI. In addition, he has given many plenary talks and Chaired many sessions at international meetings, such as ASH, ISTH, ACCP, and AHA. He has trained 12 research fellows, many of whom have gone on to become successful, independent investigators. Dr. Ginsberg’s publication list is extensive with 416 peer-reviewed publications. Many of these have appeared in high profile journals such as the New England Journal of Medicine, Annals of Internal Medicine, JAMA and Archives of Internal Medicine. He is a co-editor of a book entitled Critical Decisions in Thrombosis and Hemostasis and Editor-in-Chief of the journal Thrombosis Research.